Glenmark Pharmaceuticals Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Clean-up quarter, growth reset: India formulations grew 12.9% YoY and gained cardiac market share, while North America fell 12.4% YoY on launch delays and the P&L absorbed a ~₹447 cr exceptional charge, mostly non-cash asset impairments.
• The GLS divestment unlocked a balance-sheet reset: The ₹5,500 cr sale proceeds were offset by reserves, Monroe asset write-downs, intangible impairments and working capital rationalization, clearing legacy overhangs in a single stroke.
• RYALTRIS is the near-term growth engine: Launched in 34 markets, targeting \$80 mn+ in FY25 and a \$200–300 mn peak, with China, Brazil and Mexico approvals lining up. Management is front-ending capex to capture the ramp.
• FY26 is being framed as the breakout year: The company declined to quantify it, but pointed to RYALTRIS scaling, Monroe injectables commercializing, generic Flovent launching, and capex being pulled forward into FY25 to set it up.
• What to watch next quarter: Whether Monroe gets an FDA reinspection date, the pace of RYALTRIS market-by-market launches, and any early signal on FY26 top-line trajectory at the upcoming Investor Day.

India Business: The Standout Performer

• Broad-based outperformance: India formulations grew 12.9% YoY in Q4, with secondary sales up 11.4% versus IPM growth of 5.6%, driven by cardiac, respiratory and dermatology segments.
• Market-share gains: Glenmark moved up two positions to become the 3rd largest player in the cardiac segment, while holding the 2nd rank in dermatology and respiratory, and 17th in diabetes, per IQVIA March 2024 data.
• Consumer care steady: Primary sales reached ₹67.3 cr in Q4, with full-year growth of 3%. Flagship brand grew 15%, Candid Powder and La Shield grew 8%, and Scalpe grew 23%.
• Gross margin tailwind: The India mix helped push material cost to sales down to ~32% in Q4; management expects gross margins to stay around these levels ±1% going forward, with RYALTRIS growth providing additional support.

Glenn Saldanha: "First three years you will see very substantial growth, right, almost 80%, 100%, right, till the brand gets established. Post three years it will start slowing down, right? So, I mean we are in that phase right now where sales are doubling basically."

North America: A Reset Year with a Pipeline Bet

• Revenue declined on launch gaps: North America revenue fell 12.4% YoY and 0.9% QoQ, with management citing a lack of meaningful product launches and delays in scaling up some recent introductions.
• Monroe remediation complete, awaiting FDA: All remediation work at the Monroe facility is done; the company is requesting an FDA meeting and possible inspection in Q1 FY25, with exhibit batches being produced for the rest of the year.
• Monroe impairment taken: Of the three manufacturing lines at Monroe (nebulizer, oral solids, injectables), only injectables will be retained; the other two were written down, accounting for more than half of the total exceptional charge. Injectables commercialization is targeted for FY25.
• Generic Flovent filed as first filer: The ANDA for generic Flovent 44mcg PMDI was filed in May 2024, with launch expected in FY26; work on subsequent SKUs (110 and 220 mcg) is underway.
• New leadership installed: Marc T. Kikuchi, formerly of Dr. Reddy's, was appointed President and Business Head, North America, effective May 28, 2024.
• Pipeline building: Three ANDAs received final approval in FY24 (Saxagliptin, Apremilast, Tacrolimus 0.03%), six ANDAs were filed with the FDA, and two generic nasal spray ANDAs are awaiting approval. Another generic respiratory PMDI is planned for filing in FY25.

RYALTRIS: The Growth Narrative in One Asset

• Global rollout accelerating: As of March 2024, RYALTRIS is launched in 34 markets, with marketing applications submitted in over 80 markets. Seven additional markets were added in Q4 alone.
• Major market catalysts lining up: Mexico approval was received and launch is expected soon; Brazil approval is anticipated in FY25 or FY26; China's NDA was accepted by Grand Pharma in February 2024 with approval expected in FY26.
• Peak sales ambition: Management targets \$200–300 million in peak sales over the next 3–5 years, with FY25 sales anticipated above \$80 million. The first three years of launch are expected to see very substantial growth (~80–100%) before decelerating.
• Middle East expansion: Launch is expected in the UAE and other key Middle Eastern markets in forthcoming quarters.

Exceptional Items: The Big Clean-Up

• Q4 exceptional loss of ~₹447 cr: The charge comprised multiple non-cash and cash components tied to the post-GLS portfolio review. Full-year exceptional loss was ~₹901 cr.
• Monroe asset impairment was the largest piece: The nebulizer and oral solids lines were written down, with only injectables retained; this accounted for more than 50% of the total write-down. The remaining Monroe asset value is approximately \$150 million.
• Intangible impairments from in-licensed products: Products in-licensed over the years were reviewed during the GLS transaction and those deemed unlikely to perform were impaired, reducing the intangibles book by ₹13.3 cr (non-cash).
• Working capital rationalization: Included inventory write-downs and increased provisioning for rebates (~₹800 cr) after a review of all businesses post the GLS transaction.
• Receivables reduction of ~₹1,800 cr: Driven by better cash flow from Q3 channel inventory reduction (~₹600 cr benefit), lower Q4 growth, and the rebate provisioning increase. Receivables are expected to stabilize at 70–72 days on quarterly sales of ₹3,400–3,500 cr.

V. S. Mani: "So, about almost 12.7 crore is basically the Monroe part of it what assets that we wrote off, the balance about 13 crore is basically inventory and provisioning both of them put together under bids."

Europe & Rest of World: Mixed but Stabilizing

• Europe growth muted at 0.9% YoY: Branded markets performed well, with Poland and Slovakia delivering double-digit growth, but this was offset by softness in tender markets. Four respiratory products filed in Q4 FY23 are awaiting approval.
• RoW grew 10% YoY: Russia was a standout (ranked 9th in dermatology, 2nd in respiratory expectorants), Brazil delivered high single-digit growth in the covered market and ranked in the top 10 for chronic respiratory, and Mexico showed strong secondary sales. Kenya and South Africa also contributed growth, while Asia was subdued due to macroeconomic challenges.
• WINLEVI in-licensed for Europe: The product was in-licensed from Cosmo Pharmaceuticals for 15 European markets, the UK and South Africa, with launch expected starting FY26.
• First generic Salmeterol + Fluticasone MDI launched in Brazil during Q4 FY24, adding a respiratory complex generic to the LatAm portfolio.

Pipeline & Partnerships: Building Beyond RYALTRIS

• Envafolimab in-licensed for India and RoW: The subcutaneous PD-L1 inhibitor was in-licensed from Jiangsu Alphamab/3D Medicines, with filings planned in over 30 markets in FY25 and first market launch expected in FY26.
• JABRYUS (Abrocitinib) launched in India: Co-marketed with Pfizer for moderate-to-severe atopic dermatitis, launched in January 2024.
• Ichnos Glenmark Innovation (IGI) alliance launched: A new entity to accelerate new drug development in cancer, with R&D spend brought down substantially to ~₹5 cr in FY25 and expected to stay at that level or lower going forward.
• Capex front-loaded for FY26: The ₹700 cr capex plan for FY25 includes investment in additional manufacturing lines for RYALTRIS, generic Flovent and other products, explicitly positioned as preparation for a big FY26.

Glenn Saldanha: "And FY'26 will be a big year for the Company. That's what we believe, right, in terms of overall top line growth. So, in order to plan for FY'26, right, we are putting up the CAPEX this year, right?"

Guidance & Commitments

Key Metrics